Asceneuron

Asceneuron is the second spin-off company from the EPP fund. The company is focused on the discovery and development of effective small molecule therapeutics for Alzheimer’s disease and related neurodegenerative diseases such as tauopathies. Asceneuron is based in Geneva, Switzerland

http://www.asceneuron.com

Team Member
more about
Hakan Goker
Latest News Entry
2016/12/06
Asceneuron appoints J. Michael Ryan, M.D. as Chief Medical Officer

Lausanne, Switzerland, December 6, 2016 - Asceneuron SA, an emerging leader in the development of innovative small molecules for neurodegenerative diseases, today announced the appointment of J. Michael Ryan, M.D. as Chief Medical Officer. With over 15 years of Central Nervous System (CNS) clinical research experience, Michael brings extensive drug development expertise to Asceneuron. He will be responsible for advancing Asceneuron’s pipeline of innovative small molecules and progressing tau modifiers through the clinic.

2015/09/29
Asceneuron raises CHF 30 million in a Series A financing round led by Sofinnova Partners.

Asceneuron raises CHF 30 million in a Series A financing round led by Sofinnova Partners.

2015/04/09
Alzheimer's Drug Discovery Foundation awarded a USD 325,000 grant to support the development of Asceneuron's tau modulators

Lausanne, Switzerland – Asceneuron SA today announced that the Alzheimer’s Drug Discovery Foundation (ADDF) awarded it a USD 325,000 grant ...

2015/03/02
Asceneuron "The Road To Tau"

Lausanne, Switzerland – "The Road To Tau" - Asceneuron, an MS Ventures portfolio company ...

2015/02/17
Asceneuron Appoints Leading Experts to Scientific Advisory Board

Lausanne, Switzerland - Asceneuron SA, an emerging leader in developing novel small molecule therapeutics targeting tauopathies for Alzheimer’s and ...

all related news
all portfolio news